Who qualifies

UPDATED FEB 2026

Part of the Tylenol Autism investigation
People's Justice Research TeamUpdated February 21, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

The Most Critical Exposure Windows

The second and third trimesters are the periods most consistently associated with neurodevelopmental risk in the acetaminophen research. This is when the fetal brain undergoes the most rapid synaptogenesis (synapse formation), dopaminergic system development, and neural circuit organization — processes that acetaminophen may disrupt through its endocrine-disrupting and prostaglandin-inhibiting effects. The JAMA Psychiatry 2020 cord blood study found that acetaminophen concentrations at birth — reflecting third-trimester exposure — were most strongly predictive of ASD and ADHD risk. The 2018 AJE meta-analysis specifically noted that prolonged use (seven or more days in any trimester) was associated with elevated risk. First-trimester use has also been linked to ADHD in some studies, particularly the Norwegian Mother and Child Cohort data.

If You Don't Remember the Exact Timing

Many mothers took acetaminophen throughout pregnancy — for headaches, fever, back pain, and other discomforts — without keeping records of when or how much. This is normal and expected. You do not need to remember the exact trimester or number of doses to pursue a claim. What matters is that you used acetaminophen during pregnancy at all. Your OB's prenatal records may document acetaminophen recommendations. Pharmacy records (retrievable with a HIPAA authorization) may show fills at points during your pregnancy that correspond to the gestational calendar. Your own recollection, supported by records from pregnancy, is sufficient to establish exposure for litigation intake purposes. An attorney will help you gather the most useful documentation.

FAQ

Frequently Asked Questions

12 QUESTIONS

Yes — the litigation is still active on two fronts. First, the federal appeal: the Second Circuit Court of Appeals heard oral arguments on November 17, 2025, reviewing whether Judge Denise Cote's August 2024 dismissal of MDL-3043 was legally correct. Two of three appellate judges openly questioned the dismissal during oral argument — a significant signal that a reversal is possible. A Second Circuit ruling is expected in 2026. Second, state courts: California and Illinois are actively handling acetaminophen-autism cases under the Frye admissibility standard, which is different from and more favorable than the federal Daubert standard that closed the MDL. Families who qualify should consult an attorney now to evaluate their options in both the federal appeal and state court forums.

Dive deeper

Related Guides

1 GUIDE

The full investigation

Part of the Tylenol Autism Investigation